Trials / Active Not Recruiting
Active Not RecruitingNCT05044897
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, open label phase II clinical study is performed in patients with recurrent metastatic squamous cell carcinoma of the head and neck progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 as a single agent in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SI-B001 | administration weekly by intravenous infusion（QW）. |
Timeline
- Start date
- 2021-10-20
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2021-09-16
- Last updated
- 2025-09-26
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05044897. Inclusion in this directory is not an endorsement.